Nilo Therapeutics launched with a $101 million Series A to develop small molecules that modulate defined brain–body neural circuits controlling systemic inflammation. The round was led by The Column Group, DCVC Bio and Lux Capital, with contributions from the Gates Foundation and Alexandria Venture Investments. Founders include academics from Columbia (Charles Zuker), Yale (Ruslan Medzhitov) and Harvard (Steve Liberles); CEO Kim Seth and CSO Laurens Kruidenier said Nilo will advance preclinical programs that target vagal and other autonomic circuits identified to regulate immune activation. The approach seeks to translate neurobiology discoveries into drugs that reset immune homeostasis rather than broadly suppress immunity.